Semaglutide

Overview

Semaglutide is the most clinically validated weight loss drug currently available — and it's not particularly close. In the STEP 1 trial, patients on the 2.4 mg weekly dose lost an average of 14.9% of their body weight over 68 weeks.[1] That's a number that, before this drug class, was only achievable with bariatric surgery.

It's a 31-amino acid GLP-1 receptor agonist, meaning it mimics glucagon-like peptide-1 (GLP-1), a hormone your gut releases after you eat. Semaglutide was engineered specifically for once-weekly dosing — a structural modification over its predecessor liraglutide that dramatically extended its half-life by increasing albumin binding affinity and protecting it from enzymatic degradation.[2] That weekly dosing schedule is one reason adherence is so much better than older daily injectables.

Three branded formulations exist: Ozempic (subcutaneous injection, approved for type 2 diabetes), Wegovy (subcutaneous injection, approved for chronic weight management at a higher 2.4 mg dose), and Rybelsus (oral tablet, approved for type 2 diabetes). Same molecule, different doses and delivery systems, different approved indications.

Mechanism of Action

GLP-1 receptor agonism — appetite suppression, slowed gastric emptying, glucose-dependent insulin stimulation

The starting point is GLP-1 itself. Your gut releases GLP-1 within minutes of eating, and it does several things at once: it tells your pancreas to release insulin (but only when blood glucose is elevated, which is why it doesn't cause hypoglycemia in non-diabetics), it signals the brain's hypothalamus to reduce appetite, and it slows the rate at which your stomach empties into the small intestine.

The problem with natural GLP-1 is that it has a half-life of about two minutes. Enzymes called DPP-4 break it down almost immediately. Semaglutide was engineered to solve exactly this problem.

The structural modifications that make semaglutide work as a once-weekly drug are specific: a substitution at position 8 of the peptide chain (replacing alanine with 2-aminoisobutyric acid) blocks DPP-4 from degrading it, and a C-18 fatty diacid chain attached via a linker to lysine at position 26 gives it extremely high albumin binding affinity.[2] When semaglutide circulates in your blood, it's mostly bound to albumin — a large plasma protein that can't be filtered by the kidneys or rapidly cleared. That binding is what stretches a 2-minute half-life into ~7 days.

Once bound to GLP-1 receptors (GLP-1R), semaglutide activates pathways in the hypothalamus and brainstem that reduce hunger and increase satiety signals. This isn't just peripheral — there's meaningful CNS activity. Patients often describe not just feeling full faster, but genuinely caring less about food. The "food noise" reduction is something a lot of patients mention unprompted, and there's growing mechanistic evidence for why: GLP-1 receptors in the reward and motivation circuits of the brain appear to modulate dopaminergic responses to food cues.[3]

What the Evidence Shows

The STEP program (Semaglutide Treatment Effect in People with Obesity) was a series of Phase 3 trials that established the weight loss profile of 2.4 mg weekly semaglutide.

STEP 1 enrolled 1,961 adults with obesity or overweight plus a weight-related condition, randomized to 2.4 mg semaglutide or placebo over 68 weeks.[1] The 14.9% mean weight loss in the semaglutide group versus 2.4% in the placebo group is the headline number — but the distribution matters too. About 86% of semaglutide-treated patients lost at least 5% of body weight, and roughly 32% lost more than 20%.[1] That spread tells you this isn't a drug that produces modest uniform results; some patients respond dramatically.

The SUSTAIN trial program evaluated semaglutide across multiple comparators in type 2 diabetes management. SUSTAIN-6, the cardiovascular outcomes trial, randomized 3,297 patients with type 2 diabetes and high cardiovascular risk to semaglutide versus placebo over 104 weeks.[3] The primary cardiovascular endpoint (major adverse cardiac events — heart attack, stroke, or cardiovascular death) was reduced by 26% in the semaglutide group.[3] HbA1c (a 90-day average of blood glucose levels) dropped by 1.1 percentage points at 0.5 mg and 1.4 percentage points at 1.0 mg — clinically meaningful reductions for patients with type 2 diabetes.[3]

A 2024 real-world analysis published in JAMA Internal Medicine compared semaglutide and tirzepatide in adults with overweight or obesity — the first large head-to-head comparison in a non-diabetic population.[4] Tirzepatide produced greater weight loss at 12 months (approximately 15.3% vs. 8.3% for semaglutide in that dataset).[4] This isn't a randomized controlled trial, so confounders exist — but the direction of the finding aligns with the Phase 3 randomized trial data, where tirzepatide's 22.5% weight loss in SURMOUNT-1 exceeded semaglutide's STEP 1 results.[4]

That said, semaglutide has a longer track record, more cardiovascular outcomes data, and broader insurance coverage in most markets. The "best" drug depends on your starting point, your goals, and what your insurance will actually cover.

Side Effects
If you experience severe abdominal pain, persistent vomiting that prevents you from keeping down food or water, or signs of an allergic reaction (rash, difficulty breathing, swelling), contact your prescribing provider the same day — don't wait for your next scheduled appointment.